Elanco Animal Health (ELAN) EBIT (2017 - 2026)

Elanco Animal Health (ELAN) has 10 years of EBIT data on file, last reported at $307.0 million in Q1 2026.

• Quarterly EBIT rose 23.29% year-over-year to $307.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $853.0 million (up 211.8% YoY) and the FY2025 annual result came in at $795.0 million, up 152.48% from the prior year.
• EBIT rose to $307.0 million in Q1 2026 per ELAN's latest filing, from $158.0 million in the prior quarter.
• The five-year high for EBIT was $307.0 million in Q1 2026, with the low at -$1.6 billion in Q3 2023.
• Average EBIT over 5 years is -$324.9 million, with a median of -$498.0 million recorded in 2022.
• Year-over-year, EBIT plunged 206.98% in 2023 and soared 149.5% in 2025.
• Elanco Animal Health's EBIT stood at -$537.0 million in 2022, then fell by 19.74% to -$643.0 million in 2023, then advanced by 14.15% to -$552.0 million in 2024, then jumped by 128.62% to $158.0 million in 2025, then soared by 94.3% to $307.0 million in 2026.
• Business Quant data shows ELAN's EBIT at $307.0 million in Q1 2026, $158.0 million in Q4 2025, and $167.0 million in Q3 2025.